ANI Outperforms With Generics Amid Diversification Push
The Company’s Third Quarter Results Include Newly Acquired Assets
Reflecting the company’s acquisition of Alimera Sciences, ANI Pharmaceuticals has shared the first results that included new assets as it pushes to a more diversified business strategy.
